

In the Claims:

Please cancel claims 1-12, 19, 21-24 and 27-32 without prejudice. Please amend the claims as follows (all of the claims under consideration, whether or not amended, are presented below for the convenience of the Examiner):

13. (Amended) A method of preventing the development of an immune response to a self antigen in a subject comprising, administering an enhancing agent which activates NK-T or CD25+ cells to the subject, wherein the enhancing agent is a bacterial cell lysate or is derived from a multicellular parasite.

14. (Amended) The method of claim 17, wherein the subject is known to be at risk for the development of an immune response to a self antigen.

15. (Amended) The method of claim 17, wherein the subject is not known to be at risk for the development of an immune response to a self antigen.

16. (Amended) A method of ameliorating the symptoms of an ongoing immune response to a self antigen in a subject comprising administering an enhancing agent which activates NK-T or CD25+ cells to the subject, wherein the enhancing agent is a bacterial cell lysate or is derived from a multicellular parasite.

17. (Amended) The method of claim 13 or 16, wherein the enhancing agent is a bacterial cell lysate.

B1
18. (Amended) The method of claim 17, wherein the enhancing agent is administered orally.

20. (Amended) The method of claim 17, wherein the bacterial cell lysate is derived from a bacterium belonging to the genus *Mycobacteria*.

Please add the following new claims:

--33. The method of claim 17, wherein the enhancing agent is a lysate of bacterial cells of a genus selected from the group consisting of: *Lactobacillus*, *Bordatella*, *Corynebacterium*, *Streptococcus*, and *Hemophilus*.

B3 cont'd.
34. The method of claim 17, wherein the enhancing agent comprises lipids and glycolipids.

35. The method of claim 17, wherein the enhancing agent comprises molecules presented in the context of CD1 molecules.

36. The method of claim 17, further comprising determining the number or level of indicator T cells or the activity of indicator T cells prior to administration of the enhancing agent.

37. The method of claim 17, further comprising determining the number or level of indicator T cells or the activity of indicator T cells subsequent to administration of the enhancing agent.

38. The method of claim 37, wherein the number or level of indicator T cells is measured using an antibody that recognizes T and NK-T cell surface markers selected from a group consisting of:

i) an antibody that recognizes CD3 in combination with an antibody that recognizes at least one of CD69, CD94, and CD161; ii) an antibody that recognizes a TCR variable gene expressed region preferentially expressed by NK-T cells in combination with an antibody that recognizes at least one of CD69, CD94, and CD161; and iii) an antibody that recognizes a TCR variable gene expressed region preferentially expressed by NK-T cells in combination with an antibody that recognizes CD3 and an antibody that recognizes at least one of CD69, CD94, and CD161.

39. The method of claim 38, wherein the antibody that recognizes a TCR variable region preferentially expressed by NK-T cells recognizes $V\alpha 24$ and $V\beta 11$ and $J\alpha Q$.

40. The method of claim 37, wherein the number or level of indicator cells is measured by detecting CD4+/CD25+ T cells that are CD122 or CD132 negative.

41. The method of claim 37, wherein the level of cytokines produced by the indicator cells is determined.

42. The method of claim 17, further comprising administering an immunogen.

43. The method of claim 17, further comprising administering a TH2 cytokine.